|
[Related PubMed/MEDLINE]
Total Number of Papers: 2287
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
18F-FDG PET/CT in Tuberculosis: Can Interim PET/CT Predict the Clinical Outcome of the Patients? |
ATT, CMR, DP, FRT, TB |
| 2 |
2020 |
A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials. |
CR, DC, DEB, OS, PR, TACE |
| 3 |
2020 |
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. |
CB, CR, CTCAE, EORTC, LC, MPR-OC, ORR, PR, PTV, RTOG, SBRT |
| 4 |
2020 |
A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. |
CBR, CRC, GIST, PR, RTKs |
| 5 |
2020 |
A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors. |
MTD |
| 6 |
2020 |
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. |
ACC, AEs, DLT, DLTs, MTD, PK, RECIST, SOAT1 |
| 7 |
2020 |
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. |
DLT, IDO1, MTD, RP2D, SAEs |
| 8 |
2020 |
A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors. |
PD, PR, SAE, TRA |
| 9 |
2020 |
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. |
CHOAnome, DL, DLT, GBM, HGG, PR |
| 10 |
2020 |
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors. |
DCE-MRI, PR |
| 11 |
2020 |
A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. |
AEs, MAPK |
| 12 |
2020 |
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. |
AE's, CI, DDLS, DSRCT, LMS, MLS, ORRs, PFS, PR, SS, STS |
| 13 |
2020 |
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. |
CR, HMAs, MDS, PR |
| 14 |
2020 |
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. |
GPNMB, MMAE, ORR, OS, PFS |
| 15 |
2020 |
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). |
CI, MPM, OS, PFS-6, PR |
| 16 |
2020 |
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. |
AEs, CR, ECOG, HN, mFUP, mOS, mPFS, PR, SGC |
| 17 |
2020 |
A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. |
AGC, CERs, ICERs, OS, PFS |
| 18 |
2020 |
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. |
ACC, OS, PD-L1, PFS, RT, TGR |
| 19 |
2020 |
A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report. |
PFS, TKIs |
| 20 |
2020 |
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. |
CR, LMS, PFS, PR, STS, UPS |
| 21 |
2020 |
A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer. |
CI, CR, IVC, PR, TNBC |
| 22 |
2020 |
A Retrospective Study of Rapid Symptom Response in Bleeding Gynecologic Malignancies With Short Course Palliative Radiation Therapy: Less is More. |
CR, PD, PR, RT |
| 23 |
2020 |
A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer. |
AEs, DCR, NSCLC, ORR, PFS, PR |
| 24 |
2020 |
Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. |
CI, EGFR, NSCLC, OS, PFS, PR, TKI |
| 25 |
2020 |
Adoptive transfer of zoledronate-expanded autologous Vgamma9Vdelta2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. |
DCR, NSCLC, ORR, OS, PFS |
| 26 |
2020 |
An EGFR-Amplified Cervical Squamous Cell Carcinoma Patient with Pulmonary Metastasis Benefits from Afatinib: A Case Report. |
CN, PFS, PR |
| 27 |
2020 |
Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma. |
DCR, EGFR-TKI, mOS, mPFS, NSCLC, ORR, PD, PR |
| 28 |
2020 |
Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety. |
AEs, DCR, ORR, PD, PR, PROC, SAEs |
| 29 |
2020 |
Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients. |
DT, IT, mCRPC, PCa, PD, PET/CT, PR, PSA, PSMA |
| 30 |
2020 |
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. |
CD, NSCLC, OS, PD, PR |
| 31 |
2020 |
Autologous dendritic cells pulsed with lysate from an allogeneic hepatic cancer cell line as a treatment for patients with advanced hepatocellular carcinoma: A pilot study. |
DCs, HCC, PD, PR, TACE |
| 32 |
2020 |
Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. |
Ang-2, FGF, HCC, OR |
| 33 |
2020 |
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. |
BOR, HPV, IRC, ORR, PD-L1, PR, RECIST, SCCHN, TGF-beta, TRAEs |
| 34 |
2020 |
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. |
PFS, SCLC, SUKSES, SUKSES-C |
| 35 |
2020 |
Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents? |
DCR, ICPI, irAE, NSCLC, ORR, OS, PR |
| 36 |
2020 |
Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry. |
HI, IPSS, MDS, WPSS |
| 37 |
2020 |
Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. |
CPIs, GVHD, HR, NRM, OS, PD, PFS, PTCy, SCT |
| 38 |
2020 |
Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy. |
CR, DLT, HD-MTX, MTD, PCNSL, PD, PR, RT, TMZ |
| 39 |
2020 |
Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases. |
GC, NLR, PD, PR |
| 40 |
2020 |
Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients. |
BM, cOC |
| 41 |
2020 |
Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. |
AE, CR, DCR, HCC, mAb, ORR, OS, PD, PFS, PR, SAE |
| 42 |
2020 |
Clinical Effects of Neoadjuvant Chemotherapy in Treating Breast Cancer. |
CR, JBCS, MP, NAC, PD, PR, RECIST |
| 43 |
2020 |
Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites. |
CR, DC, PD, PR, QOL |
| 44 |
2020 |
Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China. |
AGM, CR, LC, OS, PD, PR, SBRT |
| 45 |
2020 |
Clinical Experience of Bevacizumab for Radiation Necrosis in Patients with Brain Metastasis. |
BEV, BM, FLAIR, Gd, PR, RN |
| 46 |
2020 |
Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. |
CR, CRT, ESCC, OS, PD, PFS, PR |
| 47 |
2020 |
Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function. |
CR, HCC, HR, OS, PR |
| 48 |
2020 |
Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy. |
AEs, DCR, mOS, mPFS, ORR, OS, PD, PFR, PFS, PR |
| 49 |
2020 |
Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience. |
CR, FDA, PD, PDGFRA, PFS, PR, STS |
| 50 |
2020 |
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis. |
AEs, CI, PFS, PR, TKIs |
| 51 |
2020 |
Comparison of Image-Guided Iodine-125 Seed Interstitial Brachytherapy and Local Chemotherapy Perfusion in Treatment of Advanced Pancreatic Cancer. |
VAS |
| 52 |
2020 |
Computational Modeling of Interstitial Fluid Pressure and Velocity in Non-small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery. |
CFM, DCE, IFP, LCBMs, OR, PD, sens, SRS |
| 53 |
2020 |
Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. |
CR, H. pylori, MALT, PFS, PR |
| 54 |
2020 |
Desmoid-type fibromatosis: Tumour response assessment using magnetic resonance imaging signal and size criteria. |
DF, MRI, PD, PR, RECIST |
| 55 |
2020 |
Development of prediction models for the sensitivity of oral squamous cell carcinomas to preoperative S-1 administration. |
CR, FGs, OSCC, PD, PR |
| 56 |
2020 |
Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. |
CR, CSM, DEB-TACE, ICC, OS, PD, PFS, PR |
| 57 |
2020 |
DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. |
BCLC, CR, DSM-TACE, HCC, mRECIST, PD, PR |
| 58 |
2020 |
Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAFV600E Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report. |
TKIs |
| 59 |
2020 |
Durvalumab activity in previously treated patients who stopped durvalumab without disease progression. |
PD-L1, PR |
| 60 |
2020 |
Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. |
LACC, MRCC, MSG, OS, PFS, PR |
| 61 |
2020 |
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. |
DCR, ORR, PFS, PR |
| 62 |
2020 |
Effectiveness of bronchial arterial embolization using N-butyl-2-cyanoacrylate for local control of pulmonary hilar or mediastinal tumors that are refractory to chemotherapy. |
BAE, CR, NBCA, PD, PR |
| 63 |
2020 |
Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study. |
AEs, DCR, EOC, ITT, OS, PFS, PP, PR |
| 64 |
2020 |
Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib. |
AFP, DCR, LEN, mALBI, PFS, RAM, SOR, uHCC |
| 65 |
2020 |
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients. |
ACC, AE, mTKI, PR, RR |
| 66 |
2020 |
Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. |
AEs, CI, MBC, PFS, TPC |
| 67 |
2020 |
EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patients. |
DP, EGF, PR, TKIs |
| 68 |
2020 |
Evaluation of clinical efficacy of Chemotherapy for Rhabdomyosarcoma in children. |
CR, OS, PD, PR |
| 69 |
2020 |
Evaluation of radioactive 125I seed implantation for the treatment of refractory malignant tumours based on a CT-guided 3D template-assisted technique: efficacy and safety. |
CR, CTV, PD, PR, PTV |
| 70 |
2020 |
Evaluation of the Reliability of Interim PET/CT in the Hodgkin Lymphoma. |
CR, CT, DS, FDG, HL, PET, PR |
| 71 |
2020 |
Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. |
CB, CI, CR, EEC, OR, PR |
| 72 |
2020 |
Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer. |
ctDNA, ddPCR, mCRC, PR |
| 73 |
2020 |
Extended Texture Analysis of Non-Enhanced Whole-Body MRI Image Data for Response Assessment in Multiple Myeloma Patients Undergoing Systemic Therapy. |
ADC, CR, DWI, FL, GLCM, GLRLM, IMC, IMWG, MM, NGTDM, NUN, PD, SAE, VOI |
| 74 |
2020 |
Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer. |
CR, ICRT, NSCLC, OS, PD, PR, RFS |
| 75 |
2020 |
Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. |
CR, MIBC, NAC, PD, RC, SNd, SNs |
| 76 |
2020 |
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. |
AEs, CHP, NOD2, NY-ESO-1 |
| 77 |
2020 |
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. |
DRP, MTD, PRs |
| 78 |
2020 |
Frameless Single Robotic Radiosurgery for Pulmonary Metastases in Colorectal Cancer Patients. |
CK, CR, CRC, DC, LC, mCRC, OS, PD, PFS, PR |
| 79 |
2020 |
Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis. |
CR, DCR, DSA, FUDR, HAI, mOS, ORR, PR |
| 80 |
2020 |
Identification of prognostic factors for gammadeltaT cell immunotherapy in patients with solid tumor. |
CI, FCM, HR, PD, PR |
| 81 |
2020 |
Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. |
CR, irRC, PR, RECIST |
| 82 |
2020 |
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. |
CR, DCR, FGFR1-3, ORR, PR, UCB, UTUC |
| 83 |
2020 |
Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. |
CR, HCC, mRECIST, OR, PD, PR, TACE, TGR |
| 84 |
2020 |
Intra-arterial Peptide Receptor Radionuclide Therapy using 90Y DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. |
AEs, CR, IA, IA, PD, PR, PRRT |
| 85 |
2020 |
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. |
CBR, GIST, MR, PFS, SDH, WT |
| 86 |
2020 |
Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. |
APAs, CR, PCs, PD, PR, TMZ |
| 87 |
2020 |
Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. |
CR, DCR, OS, PD, PFS, PR |
| 88 |
2020 |
Long-term scintigraphic and clinical follow up in patients with differentiated thyroid cancer and iodine avid bone metastases. |
CR, DTC, IR, PD, PR, RAI-131 |
| 89 |
2020 |
Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. |
ASCT, cHL, CR, LDC, PR, R/R |
| 90 |
2020 |
Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. |
AC, GR, HPLC, IEO, LC, MC, NECs, PR |
| 91 |
2020 |
Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising? |
EHE, hEHE |
| 92 |
2020 |
Mid-term response assessment in multiple myeloma using a texture analysis approach on dual energy-CT-derived bone marrow images - A proof of principle study. |
CR, DECT, GLCM, PR, VNC |
| 93 |
2020 |
Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer. |
CR, OC, PFS, PR |
| 94 |
2020 |
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-alpha, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. |
HCC, PR, TKIs |
| 95 |
2020 |
Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest. |
PD |
| 96 |
2020 |
Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. |
MTBs, OS, PFS, PR |
| 97 |
2020 |
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. |
BTC, CR, OC, PDAC, PR |
| 98 |
2020 |
Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma. |
--- |
| 99 |
2020 |
PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients. |
CSCs, LNs, PD, PR |
| 100 |
2020 |
PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR. |
CR, DEGs, DLBCL, EGFR, GO, IHC, KEGG, PDGFD, PR |
|
A Search Service for Abbreviation / Long Form
